Indication · Obstetrics & Gynecology
Menopause and vaginal health
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
256
Cleared or approved since 2000
PMA and De Novo
1
Higher-risk or first-of-kind devices
Breakthrough devices
0
Authorized through June 30, 2026
Recruiting device trials
18
181 device trials in all
Devices
1 devices via De Novo. PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- picoAMH ELISA
Ansh Labs, LLC · De Novo · Menopause Test System · newest 2018
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
- Halova Vaginal Ovules Versus Vaginal Estriol for Genitourinary Symptoms in Postmenopausal WomenCompleted
Perfect Care DistributionNot on our public-company list
NCT07932990 · 252 participants · Start Mar 7, 2025 · Primary completion Apr 22, 2026
Device: Halova vaginal ovules · For: Genitourinary Syndrome of Menopause (GSM); Vaginal Dryness; Vulvo Vaginal Atrophy (VVA)
Sites: Arad, Romania
180 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
Research
- Device studies on menopause across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.